Summary: Fractures of the third trochanter of the femur are an uncommon cause of hindlimb lameness in the horse. The diagnosis is easily made with ultrasonography. Reported prognosis is good after a period of rest and a progressive return to exercise. This case report describes a third trochanter fracture in a 5‐year‐old trotter mare, which is atypical in terms of both its clinical presentation and management. At the dynamic examination, a left hind lameness was only observed when harnessed at the track. Nuclear scintigraphic examination revealed a marked increase in radiopharmaceutical uptake on the third trochanter of the left femur. Radiographic and ultrasonographic findings confirmed an old complete fracture of the third trochanter of the left femur, with a displaced fragment. The mare was referred for surgical treatment in order to remove the fractured third trochanter. At the follow‐up examination, the mare was sound in hand and imaging revealed successful resection of the main fractured fragment. After a period of stall rest, the mare progressively resumed training and then racing 7.5 months after the surgery, performing at its expected level. Surgical treatment may be an option for chronic fractures of the third trochanter.
The objective of this retrospective study was to assess the safety and efficacy of a slow IV administration of 1mg/kg tiludronate in a large number of horses. Each horse that received at least one tiludronate-based treatment between 2006 and August 2019 at Virginia Equine Imaging or Fairfield Equine was included in the study. Concomitant medical treatments, preliminary NSAID injection and potential side effects were recorded after each administration. Horses for which follow-up was available over one year were subject to clinical evolution assessment via lameness grade evolution and performance data when available. Collected data suggest excellent tolerance to tiludronate with only 0,9% of the 2497 injections (1804 horses) inducing potential side effects, mild colics being the most frequent. Clinical follow-up was available over more than one year for 343 horses. Most horses (>80%) presented an initial lameness score over 1.5/5, approximately half of the population was sound by 30 days and remained so after a year. Mean lameness score improved by more than 1 grade during the follow-up period compared to initial examination. Performance data were available for 131 horses. One year after treatment, 89 (69%) horses were still competing, 73 (82%) of them at a better or similar level. These data suggest good efficacy of tiludronate over a year after treatment. Despite limitations inherent to any field study, this is the first retrospective study of the use of bisphosphonates in horses combining a large group with long-term follow-ups.